-
1
-
-
26944437399
-
-
Ananworanich, J., P. Kosalaraksa, A. Hill, U. Siangphoe, A. Bergshoeff, C. Pancharoen, C. Engchanil, K. Ruxrungtham, D. Burger, and H.-N. S. Team. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. 24:874-879.
-
Ananworanich, J., P. Kosalaraksa, A. Hill, U. Siangphoe, A. Bergshoeff, C. Pancharoen, C. Engchanil, K. Ruxrungtham, D. Burger, and H.-N. S. Team. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. 24:874-879.
-
-
-
-
2
-
-
33748170155
-
An update on therapeutic drug monitoring for antiretroviral drugs
-
Back, D., S. Gibbons, and S. Khoo. 2006. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28:468-473.
-
(2006)
Ther. Drug Monit
, vol.28
, pp. 468-473
-
-
Back, D.1
Gibbons, S.2
Khoo, S.3
-
3
-
-
18144412382
-
Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children
-
Bergshoeff, A. S., P. L. Fraaij, J. Ndagijimana, G. Verweel, N. G. Hartwig, T. Niehues, R. De Groot, and D. M. Burger. 2005. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J. Acquir. Immune Defic. Syndr. 39:63-68.
-
(2005)
J. Acquir. Immune Defic. Syndr
, vol.39
, pp. 63-68
-
-
Bergshoeff, A.S.1
Fraaij, P.L.2
Ndagijimana, J.3
Verweel, G.4
Hartwig, N.G.5
Niehues, T.6
De Groot, R.7
Burger, D.M.8
-
4
-
-
3042689560
-
Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study)
-
Breilh, D., I. Pellegrin, A. Rouzes, K. Berthoin, F. Xuereb, H. Budzinski, M. Munck, H. J. Fleury, M. C. Saux, and J. L. Pellegrin. 2004. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305-1310.
-
(2004)
AIDS
, vol.18
, pp. 1305-1310
-
-
Breilh, D.1
Pellegrin, I.2
Rouzes, A.3
Berthoin, K.4
Xuereb, F.5
Budzinski, H.6
Munck, M.7
Fleury, H.J.8
Saux, M.C.9
Pellegrin, J.L.10
-
5
-
-
33644513115
-
Ritonavir-boosted atazanavir-lopinavir combination: A pharmacokinetic interaction study of total, unbound plasma and cellular exposures
-
Colombo, S., T. Buclin, C. Franc, N. Guignard, M. Khonkarly, P. E. Tarr, B. Rochat, J. Biollaz, A. Telenti, L. A. Decosterd, and M. Cavassini. 2006. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir. Ther. 11:53-62.
-
(2006)
Antivir. Ther
, vol.11
, pp. 53-62
-
-
Colombo, S.1
Buclin, T.2
Franc, C.3
Guignard, N.4
Khonkarly, M.5
Tarr, P.E.6
Rochat, B.7
Biollaz, J.8
Telenti, A.9
Decosterd, L.A.10
Cavassini, M.11
-
6
-
-
18744374174
-
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients
-
Dailly, E., V. Reliquet, F. Raffi, and P. Jolliet. 2005. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients. Eur. J. Clin. Pharmacol. 61:153-156.
-
(2005)
Eur. J. Clin. Pharmacol
, vol.61
, pp. 153-156
-
-
Dailly, E.1
Reliquet, V.2
Raffi, F.3
Jolliet, P.4
-
7
-
-
4644333096
-
Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir
-
Delaugerre, C., J. P. Teglas, J. M. Treluyer, P. Vaz, V. Jullien, F. Veber, C. Rouzioux, M. L. Chaix, and S. Blanche. 2004. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 37:1269-1275.
-
(2004)
J. Acquir. Immune Defic. Syndr
, vol.37
, pp. 1269-1275
-
-
Delaugerre, C.1
Teglas, J.P.2
Treluyer, J.M.3
Vaz, P.4
Jullien, V.5
Veber, F.6
Rouzioux, C.7
Chaix, M.L.8
Blanche, S.9
-
8
-
-
0141612910
-
-
Dragsted, U. B., J. Gerstoft, C. Pedersen, B. Peters, A. Duran, N. Obel, A. Castagna, P. Cahn, N. Clumeck, J. N. Bruun, J. Benetucci, A. Hill, I. Cassetti, P. Vernazza, M. Youle, Z. Fox, J. D. Lundgren, and MaxCmin1 Trial Group. 2003. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. 188:635-642.
-
Dragsted, U. B., J. Gerstoft, C. Pedersen, B. Peters, A. Duran, N. Obel, A. Castagna, P. Cahn, N. Clumeck, J. N. Bruun, J. Benetucci, A. Hill, I. Cassetti, P. Vernazza, M. Youle, Z. Fox, J. D. Lundgren, and MaxCmin1 Trial Group. 2003. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. 188:635-642.
-
-
-
-
9
-
-
0019368150
-
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data
-
Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
-
(1981)
JAMA
, vol.246
, pp. 1575-1578
-
-
Ellner, P.D.1
Neu, H.C.2
-
10
-
-
9144233476
-
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial
-
Eron, J. J., J. Feinberg, H. A. Kessler, H. W. Horowitz, M. D. Witt, F. F. Carpio, D. A. Wheeler, P. Ruane, D. Mildvan, B. G. Yangco, R. Bertz, B. Bernstein, M. S. King, and E. Sun. 2004. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J. Infect. Dis. 189:265-272.
-
(2004)
J. Infect. Dis
, vol.189
, pp. 265-272
-
-
Eron, J.J.1
Feinberg, J.2
Kessler, H.A.3
Horowitz, H.W.4
Witt, M.D.5
Carpio, F.F.6
Wheeler, D.A.7
Ruane, P.8
Mildvan, D.9
Yangco, B.G.10
Bertz, R.11
Bernstein, B.12
King, M.S.13
Sun, E.14
-
11
-
-
33750546218
-
Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment- experienced HIV-infected patients receiving lopinavir/ritonavir
-
Gianotti, N., L. Galli, A. Danise, H. Hasson, E. Boeri, A. Lazzarin, and A. Castagna. 2006. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment- experienced HIV-infected patients receiving lopinavir/ritonavir. J. Med. Virol. 78:1537-1541.
-
(2006)
J. Med. Virol
, vol.78
, pp. 1537-1541
-
-
Gianotti, N.1
Galli, L.2
Danise, A.3
Hasson, H.4
Boeri, E.5
Lazzarin, A.6
Castagna, A.7
-
12
-
-
0036215227
-
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection
-
Grub, S., P. Delora, E. Ludin, F. Duff, C. V. Fletcher, R. C. Brundage, M. W. Kline, N. R. Calles, H. Schwarzwald, and K. Jorga. 2002. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 71:122-130.
-
(2002)
Clin. Pharmacol. Ther
, vol.71
, pp. 122-130
-
-
Grub, S.1
Delora, P.2
Ludin, E.3
Duff, F.4
Fletcher, C.V.5
Brundage, R.C.6
Kline, M.W.7
Calles, N.R.8
Schwarzwald, H.9
Jorga, K.10
-
13
-
-
50949105682
-
Pharmacokinetics and safety of lopinavir/ritonavir doses greater than 300 mg/m2/dose in children and adolescents with HIV infection, abstr. 937
-
February
-
Havens, P. L., M. Frank, B. Cuene, V. Decker, R. Kohler, A. Wolfe, and M. Yenter. 2004. Pharmacokinetics and safety of lopinavir/ritonavir doses greater than 300 mg/m2/dose in children and adolescents with HIV infection, abstr. 937. 11th Conf. Retrovir. Opportun. Infect., San Francisco, CA, 8 to 11 February 2004.
-
(2004)
11th Conf. Retrovir. Opportun. Infect., San Francisco, CA, 8 to 11
-
-
Havens, P.L.1
Frank, M.2
Cuene, B.3
Decker, V.4
Kohler, R.5
Wolfe, A.6
Yenter, M.7
-
14
-
-
0030896237
-
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
-
Hsu, A., G. R. Granneman, G. Witt, C. Locke, J. Denissen, A. Molla, J. Valdes, J. Smith, K. Erdman, N. Lyons, P. Niu, J. P. Decourt, J. B. Fourtillan, J. Girault, and J. M. Leonard. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
-
(1997)
Antimicrob. Agents Chemother
, vol.41
, pp. 898-905
-
-
Hsu, A.1
Granneman, G.R.2
Witt, G.3
Locke, C.4
Denissen, J.5
Molla, A.6
Valdes, J.7
Smith, J.8
Erdman, K.9
Lyons, N.10
Niu, P.11
Decourt, J.P.12
Fourtillan, J.B.13
Girault, J.14
Leonard, J.M.15
-
15
-
-
12244262297
-
Pharmacokinetic-pharmacodynamic analysis of lopinavirritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients
-
Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavirritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
-
(2003)
Antimicrob. Agents Chemother
, vol.47
, pp. 350-359
-
-
Hsu, A.1
Isaacson, J.2
Brun, S.3
Bernstein, B.4
Lam, W.5
Bertz, R.6
Foit, C.7
Rynkiewicz, K.8
Richards, B.9
King, M.10
Rode, R.11
Kempf, D.J.12
Granneman, G.R.13
Sun, E.14
-
16
-
-
0011054587
-
Trough concentration-EC50 relationship as a predictor of viral response for ABT-378/ritonavir (ABT-378/r) in treatment-experienced patients, abstr
-
Toronto, Canada
-
Hsu, A., J. Isaacson, D. Kempf, M. King, R. Rode, W. Lam, S. Bruni, B. Bernstein, E. Sun, and G. R. Granneman. 2000. Trough concentration-EC50 relationship as a predictor of viral response for ABT-378/ritonavir (ABT-378/r) in treatment-experienced patients, abstr. 171. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., Toronto, Canada.
-
(2000)
Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother
, pp. 171
-
-
Hsu, A.1
Isaacson, J.2
Kempf, D.3
King, M.4
Rode, R.5
Lam, W.6
Bruni, S.7
Bernstein, B.8
Sun, E.9
Granneman, G.R.10
-
17
-
-
33750594232
-
Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years
-
Jullien, V., S. Urien, D. Hirt, C. Delaugerre, E. Rey, J.-P. Teglas, P. Vaz, C. Rouzioux, M.-L. Chaix, E. Macassa, G. Firtion, G. Pons, S. Blanche, and J.-M. Treluyer. 2006. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob. Agents Chemother. 50:3548-3555.
-
(2006)
Antimicrob. Agents Chemother
, vol.50
, pp. 3548-3555
-
-
Jullien, V.1
Urien, S.2
Hirt, D.3
Delaugerre, C.4
Rey, E.5
Teglas, J.-P.6
Vaz, P.7
Rouzioux, C.8
Chaix, M.-L.9
Macassa, E.10
Firtion, G.11
Pons, G.12
Blanche, S.13
Treluyer, J.-M.14
-
18
-
-
34848893678
-
-
Justesen, U. S., Z. Fox, C. Pedersen, P. Cahn, J. Gerstoft, N. Clumeck, M. Losso, B. Peters, N. Obel, A. Castagna, U. B. Dragsted, J. D. Lundgren, and MaxCmin Trial Group. 2007. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. Basic Clin. Pharmacol. Toxicol. 101:339-344.
-
Justesen, U. S., Z. Fox, C. Pedersen, P. Cahn, J. Gerstoft, N. Clumeck, M. Losso, B. Peters, N. Obel, A. Castagna, U. B. Dragsted, J. D. Lundgren, and MaxCmin Trial Group. 2007. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. Basic Clin. Pharmacol. Toxicol. 101:339-344.
-
-
-
-
19
-
-
0037032931
-
Diurnal variation of plasma protease inhibitor concentrations
-
Justesen, U. S., and C. Pedersen. 2002. Diurnal variation of plasma protease inhibitor concentrations. AIDS 16:2487-2489.
-
(2002)
AIDS
, vol.16
, pp. 2487-2489
-
-
Justesen, U.S.1
Pedersen, C.2
-
20
-
-
0036768328
-
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy
-
Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
-
(2002)
Antivir. Ther
, vol.7
, pp. 165-174
-
-
Kempf, D.J.1
Isaacson, J.D.2
King, M.S.3
Brun, S.C.4
Sylte, J.5
Richards, B.6
Bernstein, B.7
Rode, R.8
Sun, E.9
-
21
-
-
34147176581
-
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect
-
Klein, C. E., Y.-L. Chiu, W. Awni, T. Zhu, R. S. Heuser, T. Doan, J. Breitenbach, J. B. Morris, S. C. Brun, and G. J. Hanna. 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immune Defic. Syndr. 44:401-410.
-
(2007)
J. Acquir. Immune Defic. Syndr
, vol.44
, pp. 401-410
-
-
Klein, C.E.1
Chiu, Y.-L.2
Awni, W.3
Zhu, T.4
Heuser, R.S.5
Doan, T.6
Breitenbach, J.7
Morris, J.B.8
Brun, S.C.9
Hanna, G.J.10
-
22
-
-
0034940996
-
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection
-
Kline, M. W., R. C. Brundage, C. V. Fletcher, H. Schwarzwald, N. R. Calles, N. E. Buss, P. Snell, P. DeLora, M. Eason, K. Jorga, C. Craig, and F. Duff. 2001. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 20:666-671.
-
(2001)
Pediatr. Infect. Dis. J
, vol.20
, pp. 666-671
-
-
Kline, M.W.1
Brundage, R.C.2
Fletcher, C.V.3
Schwarzwald, H.4
Calles, N.R.5
Buss, N.E.6
Snell, P.7
DeLora, P.8
Eason, M.9
Jorga, K.10
Craig, C.11
Duff, F.12
-
23
-
-
0042628231
-
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy
-
la Porte, C. J., J. C. Wasmuth, K. Schneider, J. K. Rockstroh, and D. M. Burger. 2003. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 17:1700-1702.
-
(2003)
AIDS
, vol.17
, pp. 1700-1702
-
-
la Porte, C.J.1
Wasmuth, J.C.2
Schneider, K.3
Rockstroh, J.K.4
Burger, D.M.5
-
24
-
-
33846117422
-
The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients
-
Maillard, A., J.-M. Chapplain, O. Tribut, D. Bentue-Ferrer, P. Tattevin, C. Arvieux, C. Michelet, and A. Ruffault. 2007. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. J. Clin. Virol. 38:131-138.
-
(2007)
J. Clin. Virol
, vol.38
, pp. 131-138
-
-
Maillard, A.1
Chapplain, J.-M.2
Tribut, O.3
Bentue-Ferrer, D.4
Tattevin, P.5
Arvieux, C.6
Michelet, C.7
Ruffault, A.8
-
25
-
-
0031054507
-
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
-
Merry, C., M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tjia, S. E. Gibbons, A. M. Breckenridge, and D. J. Back. 1997. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
-
(1997)
AIDS
, vol.11
-
-
Merry, C.1
Barry, M.G.2
Mulcahy, F.3
Ryan, M.4
Heavey, J.5
Tjia, J.F.6
Gibbons, S.E.7
Breckenridge, A.M.8
Back, D.J.9
-
26
-
-
15444377672
-
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
-
Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
-
(1996)
Nat. Med
, vol.2
, pp. 760-766
-
-
Molla, A.1
Korneyeva, M.2
Gao, Q.3
Vasavanonda, S.4
Schipper, P.J.5
Mo, H.M.6
Markowitz, M.7
Chernyavskiy, T.8
Niu, P.9
Lyons, N.10
Hsu, A.11
Granneman, G.R.12
Ho, D.D.13
Boucher, C.A.14
Leonard, J.M.15
Norbeck, D.W.16
Kempf, D.J.17
-
27
-
-
33645096370
-
Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy
-
Morse, G. D., L. M. Catanzaro, and E. P. Acosta. 2006. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis. 6:215-225.
-
(2006)
Lancet Infect. Dis
, vol.6
, pp. 215-225
-
-
Morse, G.D.1
Catanzaro, L.M.2
Acosta, E.P.3
-
28
-
-
17044457875
-
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
-
Murphy, R. L., S. Brun, C. Hicks, J. J. Eron, R. Gulick, M. King, A. C. White, Jr., C. Benson, M. Thompson, H. A. Kessler, S. Hammer, R. Bertz, A. Hsu, A. Japour, and E. Sun. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9.
-
(2001)
AIDS
, vol.15
-
-
Murphy, R.L.1
Brun, S.2
Hicks, C.3
Eron, J.J.4
Gulick, R.5
King, M.6
White Jr., A.C.7
Benson, C.8
Thompson, M.9
Kessler, H.A.10
Hammer, S.11
Bertz, R.12
Hsu, A.13
Japour, A.14
Sun, E.15
-
29
-
-
34548214568
-
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: Efficacy, safety, and predictors of response
-
Podzamczer, D., M. S. King, C. E. Klein, C. Flexner, C. Katlama, D. V. Havlir, S. L. Letendre, J. J. Eron, S. C. Brun, and B. Bernstein. 2007. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin. Trials 8:193-204.
-
(2007)
HIV Clin. Trials
, vol.8
, pp. 193-204
-
-
Podzamczer, D.1
King, M.S.2
Klein, C.E.3
Flexner, C.4
Katlama, C.5
Havlir, D.V.6
Letendre, S.L.7
Eron, J.J.8
Brun, S.C.9
Bernstein, B.10
-
30
-
-
26944478140
-
-
Ramos, J. T., M. I. De Jose, J. Duenas, C. Fortuny, R. Gonzalez-Montero, M. J. Mellado, A. Mur, M. Navarro, C. Otero, I. Pocheville, M. A. Munoz-Fernandez, and E. Cabrero on behalf of the Spanish Collaborative Group on HIV Infection in Children. 2005. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr. Infect. Dis. J. 24:867-873.
-
Ramos, J. T., M. I. De Jose, J. Duenas, C. Fortuny, R. Gonzalez-Montero, M. J. Mellado, A. Mur, M. Navarro, C. Otero, I. Pocheville, M. A. Munoz-Fernandez, and E. Cabrero on behalf of the Spanish Collaborative Group on HIV Infection in Children. 2005. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr. Infect. Dis. J. 24:867-873.
-
-
-
-
31
-
-
32644444845
-
-
Resino, S., J. M. Bellon, and M. A. Munoz-Fernandez on behalf of the Spanish Group of HIV Infection. 2006. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J. Antimicrob. Chemother. 57:579-582.
-
Resino, S., J. M. Bellon, and M. A. Munoz-Fernandez on behalf of the Spanish Group of HIV Infection. 2006. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J. Antimicrob. Chemother. 57:579-582.
-
-
-
-
32
-
-
16544384038
-
Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children
-
Resino, S., J. M. Bellon, J. T. Ramos, M. L. Navarro, P. Martin-Fontelos, E. Cabrero, and M. A. Munoz-Fernandez. 2004. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 23:923-930.
-
(2004)
Pediatr. Infect. Dis. J
, vol.23
, pp. 923-930
-
-
Resino, S.1
Bellon, J.M.2
Ramos, J.T.3
Navarro, M.L.4
Martin-Fontelos, P.5
Cabrero, E.6
Munoz-Fernandez, M.A.7
-
33
-
-
20444423799
-
Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children
-
Resino, S., I. Galan, A. Perez, J. T. Ramos, J. M. Bellon, P. M. Fontelos, M. I. de Jose, M. D. Gutierrez, E. Cabrero, and M. A. Munoz-Fernandez. 2005. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children. AIDS Res. Hum. Retrovir. 21:398-406.
-
(2005)
AIDS Res. Hum. Retrovir
, vol.21
, pp. 398-406
-
-
Resino, S.1
Galan, I.2
Perez, A.3
Ramos, J.T.4
Bellon, J.M.5
Fontelos, P.M.6
de Jose, M.I.7
Gutierrez, M.D.8
Cabrero, E.9
Munoz-Fernandez, M.A.10
-
34
-
-
7244243920
-
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
-
Ribera, E., R. M. Lopez, M. Diaz, L. Pou, L. Ruiz, V. Falco, M. Crespo, C. Azuaje, I. Ruiz, I. Ocana, B. Clotet, and A. Pahissa. 2004. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 48:4256-4262.
-
(2004)
Antimicrob. Agents Chemother
, vol.48
, pp. 4256-4262
-
-
Ribera, E.1
Lopez, R.M.2
Diaz, M.3
Pou, L.4
Ruiz, L.5
Falco, V.6
Crespo, M.7
Azuaje, C.8
Ruiz, I.9
Ocana, I.10
Clotet, B.11
Pahissa, A.12
-
35
-
-
33749174135
-
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration
-
Rosso, R., A. Di Biagio, C. Dentone, G. C. Gattinara, A. M. Martino, A. Vigano, M. Merlo, C. Giaquinto, O. Rampon, M. Bassetti, G. Gatti, and C. Viscoli. 2006. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J. Antimicrob. Chemother. 57:1168-1171.
-
(2006)
J. Antimicrob. Chemother
, vol.57
, pp. 1168-1171
-
-
Rosso, R.1
Di Biagio, A.2
Dentone, C.3
Gattinara, G.C.4
Martino, A.M.5
Vigano, A.6
Merlo, M.7
Giaquinto, C.8
Rampon, O.9
Bassetti, M.10
Gatti, G.11
Viscoli, C.12
-
36
-
-
0037344230
-
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
-
Saez-Llorens, X., A. Violari, C. O. Deetz, R. A. Rode, P. Gomez, E. Handelsman, S. Pelton, O. Ramilo, P. Cahn, E. Chadwick, U. Allen, S. Arpadi, M. M. Castrejon, R. S. Heuser, D. J. Kempf, R. J. Bertz, A. F. Hsu, B. Bernstein, C. L. Renz, and E. Sun. 2003. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 22:216-224.
-
(2003)
Pediatr. Infect. Dis. J
, vol.22
, pp. 216-224
-
-
Saez-Llorens, X.1
Violari, A.2
Deetz, C.O.3
Rode, R.A.4
Gomez, P.5
Handelsman, E.6
Pelton, S.7
Ramilo, O.8
Cahn, P.9
Chadwick, E.10
Allen, U.11
Arpadi, S.12
Castrejon, M.M.13
Heuser, R.S.14
Kempf, D.J.15
Bertz, R.J.16
Hsu, A.F.17
Bernstein, B.18
Renz, C.L.19
Sun, E.20
more..
-
37
-
-
34247147314
-
-
Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, B. Dauer, and the Frankfurt HIV Cohort. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58:1024-1030.
-
Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, B. Dauer, and the Frankfurt HIV Cohort. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58:1024-1030.
-
-
-
-
38
-
-
12144286333
-
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
-
Stephan, C., N. Hentig, I. Kourbeti, B. Dauer, M. Mosch, T. Lutz, S. Klauke, S. Harder, M. Kurowski, and S. Staszewski. 2004. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503-508.
-
(2004)
AIDS
, vol.18
, pp. 503-508
-
-
Stephan, C.1
Hentig, N.2
Kourbeti, I.3
Dauer, B.4
Mosch, M.5
Lutz, T.6
Klauke, S.7
Harder, S.8
Kurowski, M.9
Staszewski, S.10
-
39
-
-
11144357984
-
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus
-
Taburet, A. M., G. Raguin, C. Le Tiec, C. Droz, A. Barrail, I. Vincent, L. Morand-Joubert, G. Chene, F. Clavel, and P. M. Girard. 2004. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 75:310-323.
-
(2004)
Clin. Pharmacol. Ther
, vol.75
, pp. 310-323
-
-
Taburet, A.M.1
Raguin, G.2
Le Tiec, C.3
Droz, C.4
Barrail, A.5
Vincent, I.6
Morand-Joubert, L.7
Chene, G.8
Clavel, F.9
Girard, P.M.10
-
40
-
-
33745770427
-
Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children
-
van der Lee, M., G. Verweel, R. de Groot, and D. Burger. 2006. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antivir. Ther. 11:439-445.
-
(2006)
Antivir. Ther
, vol.11
, pp. 439-445
-
-
van der Lee, M.1
Verweel, G.2
de Groot, R.3
Burger, D.4
|